The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial
Abstract Background Alzheimer’s disease (AD) is characterized not only by cognitive and functional decline, but also often by the presence of neuropsychiatric symptoms. Apathy, which can be defined as a lack of motivation, is one of the most prevalent neuropsychiatric symptoms in AD and typically le...
Main Authors: | Roberta W. Scherer, Lea Drye, Jacobo Mintzer, Krista Lanctôt, Paul Rosenberg, Nathan Herrmann, Prasad Padala, Olga Brawman-Mintzer, William Burke, Suzanne Craft, Alan J. Lerner, Allan Levey, Anton Porsteinsson, Christopher H. van Dyck, the ADMET 2 Research Group |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-01-01
|
Series: | Trials |
Online Access: | http://link.springer.com/article/10.1186/s13063-017-2406-5 |
Similar Items
-
Apathy as a Treatment Target in Alzheimer's Disease: Implications for Clinical Trials
by: Adler, L., et al.
Published: (2022) -
Effect of Methylphenidate on Attention in Apathetic Alzheimer’s Disease Patients and Association with Apathy Changes in a Randomized, Placebo-controlled Trial
by: Chau, Sarah
Published: (2013) -
Effect of Methylphenidate on Attention in Apathetic Alzheimer’s Disease Patients and Association with Apathy Changes in a Randomized, Placebo-controlled Trial
by: Chau, Sarah
Published: (2013) -
Trial of Methylphenidate and Thioridazine
by: J Gordon Millichap
Published: (1991-09-01) -
FP-ADMET: a compendium of fingerprint-based ADMET prediction models
by: Vishwesh Venkatraman
Published: (2021-09-01)